Vaccine Development to Treat Alzheimer’s Disease Neuropathology in APP/PS1 Transgenic Mice
Figure 2
Analysis of Aβ burden in the brain and motor coordination of B6C3F1/J mice. (a) Mean of Aβ burden in the hippocampal and cortical regions of APPswe/PS1dE9 mice in the three treatment groups (EB101, EB102, and PBS). The mean of the Aβ burden is reduced in group A (EB101) when compared with group B (EB102) and group C (PBS) during preventive treatment and markedly reduced in the therapeutic treatment period. Data are presented as mean ± standard error of the mean (SEM). (b) Quantitative analysis of Aβ burden area in the hippocampal and cortical equivalent regions of APPswe/PS1dE9 mice treated with EB101, EB102, and PBS, represented by the number of pixels inside the stained area of each Aβ plaque. Four randomly selected mouse brain sections of preventive and therapeutic treatment groups were assessed using Pixcavator (version 4) analysis software. This figure shows that Aβ plaques of EB101-treated mice are significantly smaller in size than those of the other two treatment groups (EB102 or PBS). Data are presented as mean ± SEM. (c) Rota rod test results of motor abilities after the preventive and therapeutic treatment show no negative effect of EB101 compared to EB102- and PBS-treated mice. Wild-type mice showed no significant differences among treatment groups. Values represent the means of all six trials of a group/day ().
